Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

GSK's Flonase Sensimist (Veramyst) Switches Name On Way To OTC

Executive Summary

GSK gains approval of sNDA for Rx Veramyst (fluticasone furoate/spray) to be marketed OTC as Flonase Sensimist, an extension of the Flonase Allergy Relief.


Related Content

GSK Aims Flonase Sensimist To Counter Generic Nasal Allergy Competition
Bayer's ClariSpray Brings Hint Of Familiar Brand To Nasal Allergy Space
Umbrella Branding Is ‘Particular Concern’ As FDA Requests Research Proposals
Rhinocort Switch Makes Three In OTC Intranasal Corticosteroid Market
In Brief: GSK, Bristol/Pfizer See Approvals, Baxter Holds Its Own in Hemophilia


Related Companies